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g.2013.1Abstract Background: According to the World Health Organization, Hepatitis B virus (HBV) is
considered a major global public health problem. The genetic background may be a crucial etiologic
factor in HBV infection and its complications. Interleukin-27 (IL-27) is a newly discovered cytokine
encoded by 2 genes (EBI3 and p28). Mutations in the IL-27 gene may lead to altered cytokine pro-
duction and/or activity and thus modulate individual’s susceptibility to HVB infection.
Aim of the study: This work was designed to study the association of IL-27p28 (964A/G,
2905T/G and 4730T/C) gene promoter single nucleotide polymorphism (SNP) with the risk of Hep-
atitis B virus (HBV) in Egyptians. To the best of our knowledge, this study is the ﬁrst one that
examines IL-27p28 promoter polymorphism in Egyptian patients.
Subjects and methods: One hundred and sixteen patients with HBV infection and 101 healthy
controls were genotyped by using polymerase chain reaction/restriction fragment length polymor-
phism (PCR/RFLP) in Egyptian population.
Results: There were no signiﬁcant differences in the genotype and allele frequencies of IL-27p28
gene polymorphisms between patients and controls. Furthermore, no association was found
between the distributions of the haplotypes and HBV risk.
Conclusion: Our data suggested that polymorphisms in the IL-27 gene may not contribute to
HBV susceptibility. Further studies with large sample size should be conducted to validate these
results in Egyptian population.
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2.0011. Introduction
Hepatitis is considered a major clinical problem, according to
the World Health Organization [1]. Approximately 30% of
world populations are estimated to carry detectable HBV anti-
gens and about 5 million cases of acute Hepatitis B occur
annually [2]. More than half a million of patients worldwidein Shams University.
Figure 1 IL-27p28 (964A/G) PCR product after digestion with
Xho1 enzyme. Sample lanes (4, 8, 12 and 17) showed AG genotype
whereas the 486 bp band was digested into three bands with sizes
of 486, 347 and 121 bp. While sample lanes (3, 5, 6, 7, 9, 10, 11 and
13–16) show the AA genotype whereas the 486 bp band was not
digested. Lane 1 shows 100 bp DNA. Lane 2 shows negative
control.
54 Y.B.M. Ali et al.die annually as a result of HBV-related liver diseases [3,4]. A
large proportion of these infected individuals do not clear
the virus, which may progress to persistent infection with or
without liver disease [5]. It is estimated that 50% of male car-
riers and 14% of female carriers will eventually die of the com-
plications of cirrhosis and hepatocellular carcinoma [6]. Egypt
is among the countries with intermediate endemicity of HBsAg
[7,8]. Awadalla et al. [9] demonstrated that the prevalence rate
of HBV among 1000 Egyptian healthy volunteers’ blood do-
nors was 5%. It was more frequent in young adults and in
males than females.
An efﬁcient cellular cytotoxic T-lymphocyte (CTL) immune
response is a major contributor to HBV elimination, virus spe-
ciﬁc T cell appears to target a very few infected hepatocytes
when chronicity developed [10]. Numerous studies have shown
that cytokines are of critical importance for modulating the
intensity and duration of the host immune responses against
HBV infections [11,12].
IL-27 is a new member of the IL-6/IL-12 family that
was described in 2002 [13], it is heterodimeric cytokine
composed of the p28 subunit that was noncovalently linked to
Epstein–Barr virus-induced gene 3 protein (EBI3) subunit
[13,14]. IL-27 is produced and released early in response to
various inﬂammatory stimuli by antigen-presenting cells. IL-27
plays an essential role in a link between innate and adaptive
immunities in viral infection through binding with a heterodi-
meric receptor complex. It appears to act as early mediator of
naive T-cell proliferation, and it is a potent inducer of inter-
feron gamma (IFN-c) production (particularly in synergy with
IL-12) [15,16], which inhibit the viral replication and recruit
speciﬁc and non-speciﬁc effector immune cells besides their
role in the activation of adaptive immune response [17]. Matsui
et al. [18] and Fakruddin et al. [19] demonstrated that IL-27
could be an inhibitor of HIV-1 replication in CD4+ T cells
and macrophages and also as a potent adjuvant for epitope-
speciﬁc CTL induction against HCV infection.
Over the past few years, single nucleotide polymorphisms
(SNPs) have been proposed as the next generation of markers
for the identiﬁcation of loci associated with diseases and its
complications [20,21]. Polymorphisms in several cytokine
genes, such as IFN-c [22], tumor necrosis factor-a (TNF-a)
[23], IL-10 [24], IL-18 [25], and IL-1B [26], are considered to
be correlated with the severity of liver disease in patients with
HBV infection. Human IL-27gene is located on chromosome
16p11 and consists of ﬁve exons [27]. Recently, the 964A/G,
2905T/G and 4730T/C SNPs have been identiﬁed. Although
little is known about the SNPs of IL-27 gene in HBV develop-
ment, there is an important A versus G transition at position
964 in the promoter region. It was reported to be associated
with susceptibility to HBV [28]. In this study, we evaluated the
effect of 964A/G, 2905T/G and 4730T/C SNPs on suscepti-
bility of Egyptians to HBV infection (See Fig. 1).Figure 2 IL-27p28 (2905T/G) PCR product after digestion with
BstuI (Bsh1236I) enzyme. Sample lane 3 showed TG genotype
whereas the 120 bp band was digested into three bands with sizes
of 120, 101 and 19 bp. while sample lanes (2, 4–17) show the TT
genotype whereas the 120 bp band was not digested. Lane 1 shows
25 bp DNA ladder.2. Patients and methods
2.1. Patients and controls
One hundred and sixteen patients were enrolled in this study.
HBV infected patients were recruited from the National Liver
Institute, Menoﬁya University, Egypt. Samples included 98
males and 18 females with the mean age 42.71 ± 10.04 years(range from 22 to 70) and were clinically diagnosed and con-
ﬁrmed to be chronically infected with HBV by laboratory
investigations. One hundred and one healthy controls (68
males and 33 females) with no history of previous liver disease
(HBV and HCV infection are negative) were included in our
study. Patients with HCV or other viral infections or any other
liver diseases were excluded. Patients and controls were
matched for age, ethnicity and residence. All investigations
were performed in accordance with the Menoﬁya University,
Health and Human Ethics Clearance Committee guidelines
for Clinical Researches. Local ethics committee approved the
study protocol and informed consents were obtained from all
subjects. The work is carried out in accordance with The Code
of the World Medical Association (Declaration of Helsinki)
for experiments involving humans (See Fig. 2).
2.2. Virological assessment
All patients and controls were tested for Hepatitis B surface
antigen (HBsAg) using commercially available kits (Sorin Bio-
medica, Milan, Italy). The conﬁrmation of the presence of
HBV-DNA in HBV-positive samples was tested by a standard
polymerase chain reaction (PCR) (Roche Diagnostics Corp.,
Indianapolis, IN). HCV antibodies were tested for both groups
using the enzyme-linked immunosorbent assay (ELISA)
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(ALT), aspartate aminotransferase (AST), gamma glutamyl
transferase (GGT), alkaline phosphatase (ALP) (BioMe´rieux
S.A, Marcy l’Etoile, France), albumin (Human Gesellschaft
Fur Biochemica Und Diagnostica mbH, Wiesbaden, Germany),
and bilirubin (Roche Diagnostics Corp., Indianapolis, IN),
were all measured according to their respective manufacturer’s
kit instructions. Similarly blood urea and creatinine
(BioMe´rieux S.A) were measured for all cases following the
manual structure of manufacturer’s kit (See Fig. 3).
2.3. DNA isolation
Blood was collected by withdrawal of 5 ml venous blood from
each individual involved in this study into sterile vacutainer
tubes containing tri-potassium ethylenediaminetetraacetic acid
(EDTA.K3). Genomic DNA was extracted from whole blood-
EDTA samples by the Wizard Genomic DNA Puriﬁcation Kit
(Promega Corporation, Madison, USA) according to manu-
facturer’s instructions [29]. Extracted DNA was applied to
1% agarose gel to conﬁrm the presence of DNA. The concen-
tration of DNA in all samples was measured by using a Spec-
trophotometer (GE Healthcare Biosciences).
2.4. Genotyping of IL-27p28 SNPs
IL-27p28 SNPs were determined by PCR restriction fragment
length polymorphism (PCR-RFLP) [30]. The digested PCR
products were detected on 4% agarose gel electrophoresis.
2.4.1. Genotyping of IL-27p28 964A/G SNP (rs153109)
The PCR primers were designed as previously described [28]
forward primer: 50-GGCTGTGCTGGAAGGGAGAC-30
and reverse primer: 50-ATATCTGGGACCAGGGTTAGG-
30. A 25 ll of PCR reaction mixture contained DreamTaq
Green Master Mix 2· (Fermentas, Thermo Fisher Scientiﬁc
Inc.), 10 pmol/l of each primer (Metabion, Martinsried, Ger-
many) and 0.1 lg DNA. The PCR cycling was performed as
follows; 1 cycle of 94 C for 5 min, followed by 35 cycles of
94 C for 1 min, 56 C for 45 s, 72 C for 1 min and a ﬁnal
extension step at 72 C for 10 min. PCR reaction wasFigure 3 IL-27p28 (4730T/C) PCR product after digestion with
FauI (SmuI) enzyme. Sample lanes (2, 6, 7, 8, 9 and 11) showed
TC genotype whereas the 132 bp band was digested into three
bands with sizes of 132, 112 and 20 bp. Sample lanes (3, 5, 10,
12–16) show the TT genotype whereas the 132 bp band was not
digested. While lane 4 shows a mutant homozygous CC genotype.
Lane 1 shows 25 bp DNA ladder.performed in a Biometra thermal cycler (Biometra GmbH,
Germany). The 468 bp PCR products were visualized on 2%
agarose gel. PCR product (15 ll) was subjected to digestion
with XhoI restriction enzyme (Fermentas), which yielded
DNA fragments of 468 bp for A/A, 468/347/121 bp for A/G
and 347/121 bp for G/G genotypes in comparison to 100 bp
DNA ladder (Fermentas).
2.4.2. Genotyping of IL-27p28 2905 T/G SNP (rs17855750)
The PCR primers were designed as described previously [31]
forward primer: 50-ATCTCGCCAGGAAGCTGCGC-30 and
reverse primer: 50-CTGTTAGTGGGGGCCAGAAGGGA-
30. A 25 ll of PCR reaction mixture contained DreamTaq
Green Master Mix 2· (Fermentas), 10 pmol/l of each primer
(Metabion) and 0.1 lg DNA. The PCR cycling was performed
as follows; 1cycle of 94 C for 5 min, followed by 35 cycles of
94 C for 45 s, 66 C for 1 min, 72 C for 1 min and a ﬁnal
extension step at 72 C for 10 min. The 120 bp PCR products
were visualized on 2% agarose gel. PCR product (15 ll) was
subjected to digestion with BstuI (Bsh1236I) restriction en-
zyme (Fermentas), which yielded DNA fragments of 120 bp
for T/T, 120/101/19 bp for T/G and 101/19 bp for G/G geno-
types in comparison to 25 bp DNA ladder (Fermentas).
2.4.3. Genotyping of IL-27p28 4730T/C SNP (rs181206)
The PCR primers were designed as described previously [31]
forward primer: 50-GCTTCAGCCCTTCCATGCCC-30 and
reverse primer: 50-TCTACCTGGAAGCGG AGGTGCC-30.
A 25 ll of PCR reaction mixture contained DreamTaq Green
Master Mix 2· (Fermentas), 10 pmol/l of each primer (Meta-
bion) and 0.1 lg DNA. The reaction was carried out at 1 cycle
of 94 C for 5 min, followed by 35 cycles at 94 C for 45 s,
annealing temperature 66 C for 1 min and at 72 C for
1 min. The ﬁnal extension was completed at 72 C for
10 min. The 132 bp PCR products were visualized on 2% aga-
rose gel. PCR product (15 ll) was subjected to digestion with
FauI (SmuI) restriction enzyme (Fermentas), which yielded
DNA fragments of 132 bp for T/T, 132/112/20 bp for T/C
and 112/20 bp for C/C genotypes in comparison to 25 bp
DNA ladder (Fermentas).
2.5. Statistical analysis
The statistical analyses were performed by SPSS statistical
package version 11 (SPSS, IBM Corporation, USA). Data
were presented as means with the corresponding standard devi-
ation (SD). Comparisons among patients and controls were
performed by the independent T-test. Chi-square test was used
to compare the frequency of variables in different groups.
Odds ratios (OR) [with 95% conﬁdence interval (CI)] were cal-
culated to measure the relative risks in both control and HBV
patients. Correlation between variables was determined using
Spearman’s correlation coefﬁcient test. The haplotype frequen-
cies were estimated with linkage disequilibrium coefﬁcient
(LD), D using SNPSTAT program (available at http://bioinfo.
iconcologia.net/snpstats/start.htm) [32]. D was expressed as D0
giving the value of D as a percentage of the maximum
calculated value given the observed allele frequencies. Values
of D0 ranged between 1 and +1. A/D0/value of 1 denoted
complete linkage disequilibrium whereas a value of 0 denoted
complete linkage equilibrium.
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3.1. Clinical characteristics of the study population
All patients were positive for HBsAg, HBV-DNA, and nega-
tive for HCV antibodies. All controls were negative for
HBsAg, HBV-DNA, and negative for HCV antibodies. There
was positive correlation between the disease and male gender
(p< 0.001). The biochemical characteristics of patients and
controls enrolled in this study are shown in Table 1. Levels
of liver enzymes showed signiﬁcant increase in patients group
in comparison to the control group (p< 0.001 for ALT, AST,
GGT and ALP). Level of total bilirubin was signiﬁcantly high-
er in HBV patients (p< 0.001) in comparison to the control
group while albumin production signiﬁcantly decreased
(p< 0.001). Kidney functions were signiﬁcantly elevated with
the disease (p< 0.01 and p< 0.001 for urea and creatinine,
respectively).
3.2. Association of IL27 gene polymorphisms with the risk of
HBV infection
The genotypes distribution of IL-27p28 SNPs 964A/G and
4730T/C were in Hardy–Weinberg equilibrium while IL-27
SNP (2905 T/G) was out of the equilibrium in HBV patients
(96.5%, 2.6%, 1% (observed) vs. 91.5%, 4.1%, 0.5%
(predicted), for TT, TG, GG, respectively) (p< 0.001). The
frequencies of the IL-27 964G, 2905G and 4730C alleles
among Egyptian patients were 24%, 2.2% and 15%, respec-
tively, and that statistically was insigniﬁcant in comparison
to those frequencies observed in controls (26%, 0.5% and
12%, respectively).
Table 2 shows that AA genotype of IL-27 964A/G was
higher than AG and GG genotypes in both groups. TT geno-
type of IL-27 2905T/G was dominant genotype between both
groups, GG genotype was not detected in controls. The TT
genotype of IL-27 (4730T/C) was higher than TC and CC
genotypes in both groups. There was no signiﬁcant differenceTable 1 Biochemical characteristics of HBV patients and healthy c
Characteristics Control N= 101 (M± SD) HBV
Albumin (g/L) 4.27 ± 0.39 3.41
Creatinine (mg/dl) 0.88 ± 0.16 1.06
AST (IU/L) 21.16 ± 5.87 41.71
ALT (IU/L) 18.69 ± 5.08 44.03
Total Bilirubin (mg/dl) 0.66 ± 0.18 1.10
Direct Bilirubin (mg/dl) 0.10 ± 0.112 0.32
Urea (mg/dl) 29.05 ± 7.15 32.67
ALP (U/L) 100.79 ± 28.00 185.77
GGT (U/L) 26.17 ± 8.14 57.33
All data are presented as mean ± SD.in the distribution of all genotypes and alleles of IL-27 P28
SNPs by comparing HBV patients to controls.
3.3. Haplotype analysis
The possible four haplotype frequencies are shown in Table 3.
Linkage disequilibrium (LD) was observed between allele A at
locus 964 and allele T at locus 4730 [D0 = 0.5034, r2 =
0.122] and allele T at locus 2905 and allele T at locus 4730
[D0 = 0.9443, r2 = 0.002]. Major ATT haplotype accounted
for 70.6% and 69.3% of these four haplotypes in both the
cases and controls, respectively. Four haplotype frequencies
of the IL-27 gene in chronic HBV patients were insigniﬁcantly
different than that in healthy controls.
4. Discussion
To our knowledge, this is the ﬁrst report to attempt an evalu-
ation of the association between SNPs of IL-27p28 gene and
HBV patients in Egyptian population. Despite the existence
of effective vaccines for Hepatitis B virus from 1992 [33,34],
the prevalence of HBsAg was still 2–7% in Egypt [7,8]. Pa-
tients group had increased in the number of males over the
number of females which is in consistent with other studies
[9,35] which suggest that HBV infection might be sex biased
disease. There was a signiﬁcant association between biochem-
ical characteristics of patients in comparison to healthy con-
trols, i.e. serum albumin, creatinine, ALT, AST, total
Bilirubin, direct Bilirubin, ALP and GGT. Similarly, Bantel
et al. [36], Kronenberger et al. [37] and Sumer et al. [38] found
that levels of liver enzymes might be biased in HBV infection.
IL-27 is a pleiotropic cytokine that can do proinﬂammatory
and anti-inﬂammatory functions. In CD4+ and CD8+ T cells,
as well as in natural killer (NK) cells, IL-27 promotes the
expression of the transcription factor T-bet and the cytokines
IL-10 and IFN-c [39]. It also limits the production of IL-17
by CD4+ T cells and NK cells [40,41]. In response to IL-27,
B cell subsets increase their proliferation and antibody produc-ontrols.
N= 116 (M± SD) p-Value Correlation with disease
± 0.58 p< 0.001 r= 0.652
p< 0.001
± 0.21 p< 0.001 r= 0.422
p< 0.001
± 18.50 p< 0.001 r= 0.590
p< 0.001
± 27.08 p< 0.001 r= 0.534
p< 0.001
± 0.46 p< 0.001 r= 0.520
p< 0.001
± 0.39 p< 0.001 r= 0.343
p< 0.001
± 9.31 p< 0.01 r= 0.212
p< 0.01
± 100.88 p< 0.001 r= 0.488
p< 0.001
± 23.68 p< 0.001 r= 0.651
p< 0.001
Table 2 The genotype and allele frequencies of IL-27 polymorphisms in HBV patients and controls.
Polymorphisms Control (N= 101) N (%) HBV (N= 116) N (%) OR (95% CI) p-Value
IL-27 964A/G
Alleles
A 150 (74%) 177 (76%) 0.0896 (0.58–1.39) NS
G 52 (26%) 55 (24%) 1.12 (0.72–1.7) NS
IL-27 964A/G
Genotypes
AA 61 (60.4%) 69 (59.5%) 0.963 (0.559–1.659) NS
AG 28 (27.7%) 39 (33.6%) 1.32 (0.74–2.36) NS
GG 12 (11.9%) 8 (6.9%) 0.55 (0.22–1.40) NS
IL-27 2905 T/G
Alleles
T 201 (99.5) 221 (97.8) 4.55 (0.53–39.26) NS
G 1 (.5) 5 (2.2) 0.22 (0.03–1.89) NS
IL-27 2905 T/G
Genotype
TT 100 (99) 109 (96) 0.273 (0.030–2.470) NS
TG 1 (1) 3 (3) 2.67 (0.27–26.12) NS
GG 0 (0) 1 (1) 1.009 (0.99–1.03) NS
IL-27 4730T/C
Alleles
T 177 (88%) 196 (85) 1.23 (0.71–2.14) NS
C 25 (12%) 34 (15) 0.814 (0.47–1.42) NS
IL-27 4730T/C
Genotype
TT 77(76.2) 85 (73.9) 0.88(0.48–1.64) NS
T/C 23 (22.8) 26 (22.6) 3.60(0.39–32.78) NS
CC 1 (1) 4 (3.5) 1.132 (0.610–2.103) NS
Table 3 Haplotype frequencies of IL-27 gene in the patients with HBV and in controls.
IL-27 gene (964/2905/4730) haplotypes Control (N= 101) N (%) HBV (N= 116) N (%) OR (95% CI) p-Value
ATT 70 (69.3) 82 (70.6) 1.00 NS
GTT 18 (17.8) 16 (13.7) 0.75 (0.45–1.26) NS
GTC 8 (7.9) 12 (10.34) 1.39 (0.66–2.91) NS
ATC 5 (4.9) 6 (5.17) 0.99 (0.43–2.28) NS
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inﬂammatory responses by increasing expression of IL-1,
TNF-a, and IL-6 [44]. However, in neutrophils, IL-27 limits
cytokine secretion of IL-6 and IL-12p40 [45]. In human macro-
phages, IL-27 can inhibit their responsiveness to proinﬂamma-
tory cytokines such as IL-1 and TNF-a by down-regulating
expression of their cognate receptors [46].
Since IL-27 is important for Th1 promotion and persistent
Th1 responses can lead to excessive cell-mediated immunity
and uncontrolled tissue damage, it is reasonable to speculate
that the incidence of fatal hepatitis in chronic Hepatitis B pa-
tients may be in part due to the high production of IL-27 [47].
Thus, the present study was designed to examine the effect of
IL-27 SNPs on susceptibility to HBV infection. The present
study observed insigniﬁcant change in genotypes and allele fre-
quencies of IL-27p28 (964A/G, 2905T/G, 4730T/C) poly-
morphisms with HBV infection. Similarly, Peng et al. [48]
observed that there were no signiﬁcant differences in the geno-
type and allele frequencies of IL-27 gene polymorphisms be-
tween chronic HBV patients and healthy controls. Incontrast to our study, Wang et al. [28] observed that
IL-27p28 (964A/G) SNP was associated with the progression
of chronic Hepatitis B in Chinese, so the mechanism of IL-27
with the disease may be affected with its polymorphism in
HBV patient.
The major haplotype between both groups was ATT haplo-
type. Haplotype frequencies of the IL-27p28 gene were not
associated with chronic HBV patients and this was consistent
to the data presented by Peng et al. [48].5. Conclusion
This study observed that there was no signiﬁcant association
between SNPs of IL-27p28 and the risk of HBV infection in
Egyptian population. However, because of the relatively small
sample size and strong LD of this study, further studies with
large sample size are needed to validate these results and ex-
plore the effect of different environmental factors on these re-
sults, especially in Egyptian populations.
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